The Clinical Development Program of Lixisenatide: A Once-Daily Glucagon-Like Peptide-1 Receptor Agonist

Lixisenatide (AVE0010) is a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type 2 diabetes. Phase II dose-finding and pharmacodynamic studies identified the 20 µg once-daily dose as having the optimum combination of efficacy, convenience and tolerability. Lixise...

Descripción completa

Detalles Bibliográficos
Autor principal: Bain, Stephen C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2014
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269639/
https://www.ncbi.nlm.nih.gov/pubmed/25027491
http://dx.doi.org/10.1007/s13300-014-0073-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4269639/
https://www.ncbi.nlm.nih.gov/pubmed/25027491
http://dx.doi.org/10.1007/s13300-014-0073-z

Ejemplares similares